LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

Gong, Yaoqin; Slee, Roger B.; Fukai, Naomi; Rawadi, Georges; Roman-Roman, Sergio; Reginato, Anthony M.; Wang, Hongwei; Cundy, Tim; Glorieux, Francis H.; Lev, Dorit; Zacharin, Margaret; Oexle, Konrad; Marcelino, Jose; Suwairi, Wafaa; Heeger, Shauna; Sabatakos, George; Apte, Suneel; Adkins, William N.; Allgrove, Jeremy; Arslan-Kirchner, Mine; Batch, Jennifer A.; Beighton, Peter; Black, Graeme C. M.; Boles, Richard G.; Boon, Laurence M.; Borrone, Carla; Brunner, Han G.; Carle, Georges F.; Dallapiccola, Bruno; De Paepe, Anne; Floege, Barbara; Halfhide, Melissa Lees; Hall, Bryan; Hennekam, Raoul C.; Hirose, Tatsuo; Jans, Ab; Jüppner, Harald; Kim, Chong Ae; Keppler-Noreuil, Kim; Kohlschuetter, Alfried; LaCombe, Didier; Lambert, Marie; Lemyre, Emmanuelle; Letteboer, Tom; Peltonen, Leena; Ramesar, Rajkumar S.; Romanengo, Marta; Somer, Hannu; Steichen-Gersdorf, Elisabeth; Steinmann, Beat; Sullivan, Beth; Superti-Furga, Andrea; Swoboda, Walter; van den Boogaard, Marie-José; Van Hul, Wim; Vikkula, Miikka; Votruba, Marcela; Zabel, Bernhard; Garcia, Teresa; Baron, Roland; Olsen, Bjorn R.; Warman, Matthew L.

Affiliations

¹The Osteoporosis-Pseudoglioma Syndrome Collaborative Group

Abstract

In humans, low peak bone mass is a significant risk factor for osteoporosis. We report that LRP5, encoding the low-density lipoprotein receptor-related protein 5, affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). We find that OPPG carriers have reduced bone mass when compared to age- and gender-matched controls. We demonstrate LRP5 expression by osteoblasts in situ and show that LRP5 can transduce Wnt signaling in vitro via the canonical pathway. We further show that a mutant-secreted form of LRP5 can reduce bone thickness in mouse calvarial explant cultures. These data indicate that Wnt-mediated signaling via LRP5 affects bone accrual during growth and is important for the establishment of peak bone mass.

Links

DOI: 10.1016/S0092-8674(01)00571-2

PubMed: 11719191

WoS: 000172272900011

History

Received: 2001-04-2

Revised: 2001-11-16

Online: 2001-11-27

Cited Works (4)

Year	Entry
1987	Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. December 1987;2(6):595-610.
1986	Riggs BL, Melton LJ III. Involutional osteoporosis. NEJM. June 26, 1986;314(26):1676-1686.
2000	Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM. Normative data for iliac bone histomorphometry in growing children. Bone. February 2000;26(2):103-109.
2001	NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. February 14, 2001;285(6):785-795.

Cited By (56)

Year	Entry
2013	Hum JM. Signaling Mechanisms That Suppress the Anabolic Response of Osteoblasts and Osteocytes to Fluid Shear Stress [PhD thesis]. Bloomington, IN: Indiana University; September 2013.
2002	Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao S-C, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. A mutation in the LDL receptor–related protein 5 gene results in the autosomal dominant high–bone-mass trait. Am J Hum Genet. January 2002;70(1):11-19.
2008	Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. April 2008;42(4):606-615.
2012	Marsell R, Sisask G, Nilsson Y, Sundgren-Andersson AK, Andersson U, Larsson S, Nilsson O, Ljunggren Ö, Jonsson KB. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone. March 2012;50(3):619-627.
2020	Mumm S, Gottesman GS, Wenkert D, Campeau PM, Nenninger A, Huskey M, Bijanki VN, Veis DJ, Barnes AM, Marini JC, Stolina M, Zhang F, McAlister WH, Whyte MP. Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation. Bone. January 2020;130:115047.
2020	Schupbach D, Comeau-Gauthier M, Harvey E, Merle G. Wnt modulation in bone healing. Bone. September 2020;138:115491.
2021	Goel D, Vohora D. Liver X receptors and skeleton: current state-of-knowledge. Bone. March 2021;144:115807.
2021	Brommage R, Jeter-Jones S, Xiong W, Liu J. MicroCT analyses of mouse femoral neck architecture. Bone. April 2021;145:115040.
2021	Helderman RC, Whitney DG, Duta-Mare M, Akhmetshina A, Vujic N, Jayapalan S, Nyman JS, Misra BB, Rosen CJ, Czech MP, Kratky D, Rendina-Ruedy E. Loss of function of lysosomal acid lipase (LAL) profoundly impacts osteoblastogenesis and increases fracture risk in humans. Bone. July 2021;148:115946.
2021	Arshad F, Bishop N. Osteogenesis imperfecta in children. Bone. July 2021;148:115914.
2021	Morrell AE, Robinson ST, Ke HZ, Holdsworth G, Guo XE. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody. Bone. August 2021;149:115967.
2002	Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. April 2002;2(4):389-406.
2005	Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. May 2005;8(5):727-738.
2005	Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. May 2005;8(5):739-750.
2006	Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. August 15, 2006;133(16):3231-3244.
2003	Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. January 2003;22(23):6267-6276.
2010	Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. June 2010;31(3):266-300.
2013	Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr Rev. October 2013;34(4):658-690.
2012	Thompson WR, Rubin CT, Rubin J. Mechanical regulation of signaling pathways in bone. Gene. July 25, 2012;503(2):179-193.
2005	Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. May 20, 2005;280(20):19883-19887.
2005	Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. July 22, 2005;280(29):26770-26775.
2006	Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. August 18, 2006;281(33):23698-23711.
2006	Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown EL, Hill AA, Akhter MP, Johnson ML, Recker RR, Komm BS, Bex FJ. Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. October 20, 2006;281(42):31720-31728.
2008	Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. February 29, 2008;283(9):5866-5875.
2015	Oftadeh R, Perez-Viloria M, Villa-Camacho JC, Vaziri A, Nazarian A. Biomechanics and mechanobiology of trabecular bone: a review. J Biomech Eng. January 2015;137(1):010802.
2020	Mäkitie RE, Kämpe A, Costantini A, Alm JJ, Magnusson P, Mäkitie O. Biomarkers in WNT1 and PLS3 osteoporosis: altered concentrations of DKK1 and FGF23. J Bone Miner Res. May 2020;35(5):901-912.
2020	Yorgan TA, Rolvien T, Stürznickel J, Vollersen N, Lange F, Zhao W, Baranowsky A, Rosenthal L, Hermans‐Borgmeyer I, Sharaf A, Karsak M, David J, Oheim R, Amling M, Schinke T. Mice carrying a ubiquitous R235W mutation of Wnt1 display a bone‐specific phenotype. J Bone Miner Res. September 2020;35(9):1726-1737.
2021	Stürznickel J, Rolvien T, Delsmann A, Butscheidt S, Barvencik F, Mundlos S, Schinke T, Kornak U, Amling M, Oheim R. Clinical phenotype and relevance of LRP5 and LRP6 variants in patients with early‐onset osteoporosis (EOOP). J Bone Miner Res. 2021;36(2):271-282.
2021	Stürznickel J, Jähn-Rickert K, Zustin J, Hennig F, Delsmann MM, Schoner K, Rehder H, Kreczy A, Schinke T, Amling M, Kornak U, Oheim R. Compound heterozygous frameshift mutations in MESD cause a lethal syndrome suggestive of osteogenesis imperfecta type XX. J Bone Miner Res. June 2021;36(6):1077-1087.
2022	Schindeler A, Lee LR, O'Donohue AK, Ginn SL, Munns CF. Curative cell and gene therapy for osteogenesis imperfecta. J Bone Miner Res. May 2022;37(5):826-836.
2022	Costantini A, Mäkitie RE, Hartmann MA, Fratzl-Zelman N, Zillikens MC, Kornak U, Søe K, Mäkitie O. Early-onset osteoporosis: rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen. J Bone Miner Res. September 2022;37(9):1623-1641.
2023	Kalyanaraman H, China SP, Cabriales JA, Moininazeri J, Casteel DE, Garcia JJ, Wong VW, Chen A, Sah RL, Boss GR, Pilz RB. Protein kinase G2 is essential for skeletal homeostasis and adaptation to mechanical loading in male but not female mice. J Bone Miner Res. January 2023;38(1):171-185.
2005	Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. December 2005;115(12):3318-3325.
2006	Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. May 2006;116(5):1202-1209.
2002	Seeman E. Pathogenesis of bone fragility in women and men. Lancet. May 25, 2002;359(9320):1841-1850.
2004	Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. April 24, 2004;363(9418):1377-1385.
2006	Sambrook P, Cooper C. Osteoporosis. Lancet. June 17, 2006;367(9527):2010-2018.
2013	Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. February 2013;19(2):179-192.
2012	Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. January 2012;13(1):27-38.
2003	Harada S-i, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. May 15, 2003;423(6937):349-355.
2002	Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor–related protein 5. NEJM. May 16, 2002;346(20):1513-1521.
2007	Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. NEJM. August 30, 2007;357(9):905-916.
2019	Campi AE. Mechanosensitive Ca²⁺ Signaling of Ex Vivo Osteocytes in Aging and Treatment [PhD thesis]. Columbia University; 2019.
2014	Ko FC. In Vivo Noninvasive Mouse Model of Load Induced Osteoarthritis [PhD thesis]. Ithaca, NY: Cornell University; May 2014.
2016	Oei L. Epidemiological, Radiological and Genetic Aspects of Endocrine Bone Diseases [PhD thesis]. Erasmus University Rotterdam; December 14, 2016.
2012	Mulholland B. The Role of Post-Menopausal Osteoporosis in Bone Metastatic Breast Cancer and the Effect of Monocyte Chemoattractant Protein-1 [PhD thesis]. Brisbane, Australia: Griffith University; April 2012.
2019	Bullock WA. The Role of Wnt Signaling in Bone Mechanotransduction [PhD thesis]. Indianapolis, IN: Indiana University – Purdue University Indianapolis; November 2019.
2015	Oftadeh R. Hierarchical Analysis and Multiscale Modelling of Cellular Structures: From Meta Materials to Bone Structure [PhD thesis]. Northeastern University; December 2015.
2005	Pitner ND. Evaluation of the Role of Low-Density Lipoprotein Receptor-Related Protein 5 (lrp5) in Regulating Bone Mass [PhD thesis]. Purdue University; December 2005.
2010	Niziolek PJ. The Role of Low Density Lipoprotein Receptor-Related Protein 5 (LRP5) High Bone Mass Mutations in Bone Metabolism [PhD thesis]. Purdue University; August 2010.
2008	Arnsdorf EJ. Guiding Osteogenic Lineage Commitment: The Role of Mesenchymal Stem Cell Biology and the Mechanical Microenvironment [PhD thesis]. Stanford University; September 2008.
2017	Morse AR. The Role of Wnt/β-Catenin Antagonists - Sclerostin and DKK1 - in Bone Homeostasis and Mechanotransduction [PhD thesis]. University of Sydney; 2017.
2016	Chang JC. Understanding the Role of Sclerostin in Post-Traumatic Osteoarthritis Development in Mice [PhD thesis]. Merced, CA: Merced, University of California; 2016.
2016	Sebastian A. High-Throughput Analysis of WNT Signaling Pathway in Osteoblasts [PhD thesis]. Merced, CA: Merced, University of California; 2016.
2011	Ferreira JNAR. Engineering Hydroxyapatite-Gelatin Nanocomposites With MAPC Cells for Calvarium Bone Regeneration [PhD thesis]. University of North Carolina at Chapel Hill; 2011.
2013	Bernick JH. A Preclinical Assessment of Lithium to Enhance Fracture Healing [Master's thesis]. University of Toronto; 2013.